ClinicalTrials.gg
Active, not recruitingNCT07123480MOST-CRUpdated Sep 30, 2026

The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance

An interventional study of Usual Care Group and More Support and Tools in Ethics, Cardiac Rehabilitation and Coronary Heart Disease (CHD), sponsored by Baystate Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Baystate Medical Center · Not applicable, Interventional, and Health services research

How we know

Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.

Planned enrollment
103rd of 184
160 · median 200
Started
2025
with 3 others
No phase
78 of 274
6 open now
Primary completion
2025-09
later than 2 of 22 live
Registered
272nd of 274
by date

Among the 274 studies in Coronary Disease with a site in United States, this one is the 103rd largest by planned enrollment of the 184 interventional ones that give a count, is one of 4 that started in 2025, is one of 78 with no phase, reaches primary completion later than 2 of the 22 other live ones, and was the 272nd registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Coronary Disease with a site in United States, or all of them as a file.
02

Study summary

Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend.

New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation.

In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project.

The two main goals of this study is to understand:

  1. If the consent approach type impacts participation rates in the research study
  2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.
Read the detailed description

Cardiac Rehabilitation (CR) is a guideline-recommended therapy that helps patients improve their health and longevity. It is underused, especially among older, sicker, and minority populations. Guidelines make strong recommendations for use among all patients, and there are ongoing national initiatives to improve utilization. At Baystate, cardiac rehabilitation attendance rates are improving, but investigators are still seeking additional strategies to further encourage participation. If the investigators succeed, patients will live longer, healthier lives, thus embodying beneficence.

However, the typical 10-12 page consent form is a major barrier to successful study completion with participation rates in typical clinical trials of 20% of eligible patients. More importantly, it introduces an important selection bias in the population by finding patients who are more responsive to interventions. It also shifts the population towards patients away from underrepresented minorities and yields results that are less applicable to real-world settings with clinical populations. In short, this selection bias is inconsistent with the ethical principle of justice, which states that the same population that is expected to benefit from the research should also be the population that bears the burden of the research. Thus, alternate forms of informed consent are needed to assure a representative population and scientific results that can be confidently generalized.

First, to address issues of consent, the investigators will determine the impact of four different ethical approaches to consent (full consent with signature, 3-page summary consent with signature, 1-page opt-out waiver - no signature, or Non-Consenting (NC) cohort - where patients can refuse any intervention) on study enrollment rate and population representativeness.

Second, the investigators will assess the feasibility and utilization of a multi-dimensional intervention to increase CR enrollment. These will include combining a financial incentive, case management, text messaging program, and physical activity coaching, all with the goal of increasing CR enrollment. The investigators will assess the acceptance rate of intervention components and the overall feasibility of the proposed intervention in preparation for larger clinical trials.

Patients will be randomized to 1 of 4 consent approaches shown below. All consent documents and corresponding waivers were submitted to a full board IRB and approved.

  • Full consent form. This is the typical 10 to 12-page consent form at Baystate Medical Center. This has the 3-4-page summary and the 6-8 pages of technical details. It has unalterable language provided by the Baystate Institutional Review Board (IRB) and Baystate Legal with an 11th-grade Keiser-Fleischer reading grade level. All elements of consent are included. A full HIPPA waiver is included. Signature is required.
  • Brief consent form. This 3-4-page consent form summarizes the study in a shorter form. All essential information is retained, and there is considerably less required legal language. Signature is required. The investigators provided a justification for alteration of consent to our IRB.
  • 1 page opt-out Waiver. This 1-page description includes a brief description of the study, its purposes, and goals. It gives the patient a chance to opt-out, but does not require a signature. Patients' consent is implied unless they indicate otherwise. The investigators provided a justification for alteration of consent to their IRB.
  • Non-Consenting (NC) Cohort. Patients are told they are participating in a Cardiac Rehabilitation Project, but are given the option to decline any intervention they are not interested in. The investigators will not provide written or explicit verbal consent prior to participating. The investigators provided a Justification for alteration of consent to their IRB.

Patients who agree to participate by signing a consent form, by not opting out, or by being randomized to the non-consent group will be re-randomized to either the Usual Care or MOST group. Additional details of these interventions are found below.

If patients consent, do not opt-out, or are randomized to the non-consenting cohort, they will be re-randomized 1:1 to either usual care or a multifactorial CR intervention. This intervention will include four components: financial incentives, text messaging, case management, and physical activity coaching, combined as a single intervention.

The primary outcome will be the proportion of patients (%) participating in the clinical trial. The secondary outcome will be enrollment in CR within 3 months of hospital discharge.

All interventions are minimal risk. They are typically found in routine clinical medicine and have been used without difficulty in other settings. In any group, patients can refuse any or all components of the intervention, thus respecting patient autonomy. If patients respond and attend CR, they will gain health benefits, which is consistent with the ethical principle of beneficence.

03

Conditions studied

  • Ethics
  • Cardiac Rehabilitation
  • Coronary Heart Disease (CHD)
  • Heart Failure
  • Percutaneous Coronary Intervention (PCI)
  • Aortic Valve Replacement
  • Myocardial Infarction (MI)

Keywords

  • Cardiac Rehabilitation
  • Informed Consent Approach
  • Phase 2
  • implementation science
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only Baystate Medical Center (Springfield, Massachusetts ) adult patients over age 18 who are admitted to Baystate Medical Center Hospital with a non-surgical qualifying diagnosis for outpatient CR will be included. Common diagnoses include all patients with myocardial infarction, stable angina, percutaneous coronary intervention, transcutaneous aortic/mitral valve replacement, and heart failure.

Exclusion criteria

Exclusion Criteria:

- Patients with coronary artery bypass graft surgery, heart valve surgery, or other open-heart surgical procedures will be excluded, as these patients are much more likely attend CR, typically around 70%. In addition, patients who are referred to CR programs outside the region, where enrollment cannot be tracked, will be excluded.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Other
    Long Consent

    Standard Consent approach (typically 10-12 pages)

    Behavioral: Usual Care Group · Behavioral: More Support and Tools

  • Other
    Short Consent

    Three page key Information consent

    Behavioral: Usual Care Group · Behavioral: More Support and Tools

  • Other
    Opt-Out

    1 page opt-out consent approach

    Behavioral: Usual Care Group · Behavioral: More Support and Tools

  • Other
    Non-Consenting

    No consent

    Behavioral: Usual Care Group · Behavioral: More Support and Tools

Interventions

  • BehavioralUsual Care Group

    Standard of care to encourage cardiac rehabilitation attendance.

  • BehavioralMore Support and Tools

    More Support and Tools includes the following: monetary incentive, text messages, case management, and physical activity coaching. The investigators will start providing support and tools while patients are still in the hospital and continue this support weekly after discharge. Intervention participants will receive a monetary incentive both in the hospital and upon attending cardiac rehabilitation. The support (case management) and tools (physical activity coaching and text messages) will continue for up to 3 months or until the individual attends cardiac rehabilitation, whichever occurs first. Participants can decline any or all support or tools.

06

What researchers measure

Primary outcomes

  1. Informed Consent Approach Participation

    The proportion of patients (%) participating in the clinical trial.

    Time frame: Baseline

Secondary outcomes

  1. Cardiac Rehabilitation Attendance

    The proportion (%) of patients who attend 1 or more sessions of cardiac rehabilitation

    Time frame: Up to to 3 months after hospital discharge, or cardiac rehabilitation attendance, whichever comes first.

  2. Age Representativeness of Consenting Groups

    Each consent group will be analyzed based on the demographics of patients participating. The age characteristics of each consent group will be measured in years.

    Time frame: Baseline

  3. Sex Representativeness of Consenting Groups

    Each consent group will be analyzed based on the demographics of patients participating. The sex characteristics of each consent group will be measured as male, female, or other.

    Time frame: Baseline

  4. Race Representativeness of Consenting Groups

    Each consent group will be analyzed based on the demographics of patients participating. The race characteristics of each consent group will be measured using the five NIH racial categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and White).

    Time frame: Baseline

  5. Ethnicity Representativeness of Consenting Groups

    Each consent group will be analyzed based on the demographics of patients participating. The ethnicity characteristic of each consent group will be measured using the NIH defined categories (Hispanic or Latino, and Not Hispanic or Latino).

    Time frame: Baseline

  6. Cardiac Rehabilitation Qualifying Diagnosis Representativeness of Consenting Groups

    Each consent group will be analyzed based on the demographics of patients participating. The cardiac rehabilitation qualifying diagnosis characteristic of each consent will be measured.

    Time frame: Baseline

  7. The Porportion of Intervention Accepted

    The proportion of patients (%) who accept each intervention (financial incentives, case management, physical activity coaching, and text messaging) will be measured.

    Time frame: Up to to 3 months after hospital discharge, or cardiac rehabilitation attendance, whichever comes first

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified individual data may be shared, but given that patients are randomized to 4 different informed consent approaches, one of which is a non-consent group, it is unclear if the Institutional Review Board (IRB) would allow data sharing. At this time, data sharing seems unlikely.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Sep 2025, 1 month.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 1 month is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jan 2026 → Sep 2025 and completion Jun 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 14, 2025
StartActual
Jul 16, 2025
Primary completionActual
Sep 4, 2025was Jan 2026
CompletionEst.
Mar 8, 2027was Jun 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 31, 2026→Sep 4, 2025 (actual)
Sep 30, 2026
Study completion
Jun 30, 2026→Mar 8, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Jan 31, 2026→Sep 4, 2025 (now actual)
    Study completion Jun 30, 2026→Mar 8, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07123480
Lead sponsor
Baystate Medical Center
Responsible party
Quinn Pack, MD, MSc (Medical Director of Cardiac Rehabilitation and Wellness, Baystate Medical Center) — Principal investigator
First posted
Aug 14, 2025
Start date
Jul 16, 2025
Primary completion
Sep 4, 2025
Completion
Mar 8, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Quinn R Pack, MD, MSc
principal investigator · Baystate Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion